Substance use disorders (SUDs) remain a global public health crisis, affecting millions with devastating social, economic, and health consequences. Traditional treatments, including behavioral therapies and pharmacotherapies, often face challenges like high relapse rates and limited efficacy. In this context, cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa, has emerged as a potential therapeutic agent for…
